Osteoinductive LIM mineralization protein-1 suppresses activation of NF-κB and selectively regulates MAPK pathways in pre-osteoclasts

Bone

Volumn 46, Issue 5, 2010, Pages 1328-1335

  Liu, Hui ^a,b   Bargouti, Maggie ^b   Zughaier, Susu ^b   Zheng, Zhaomin ^a   Liu, Yunshan ^b   Sangadala, Sreedhara ^b   Boden, Scott D ^b   Titus, Louisa ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bone loss; LIM mineralization protein 1 (LMP 1); Mitogen activated protein kinases (MAPKs); Nitric oxide (NO); Nuclear factor kappa B (NF B)

Indexed keywords

ANTIINFLAMMATORY AGENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT LIM MINERALIZATION PROTEIN 1; REGULATOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CELL NUCLEUS; CELL STIMULATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OSTEOCLASTS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77951253403     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.11.017     Document Type: Article

References (37)

1. Boden S.D., Liu Y., Hair G.A., Helms J.A., Hu D., Racine M., et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 1998, 139:5125-5134.
2. Boden S.D., Titus L., Hair G., Liu Y., Viggeswarapu M., Nanes M.S., et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 1998, 23:2486-2492.
3. Viggeswarapu M., Boden S.D., Liu Y., Hair G.A., Louis-Ugbo J., Murakami H., et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J. Bone. Joint. Surg. Am. 2001, 83-A:364-376.
4. Liu Y., Hair G.A., Boden S.D., Viggeswarapu M., Titus L. Overexpressed LIM mineralization proteins do not require LIM domains to induce bone. J. Bone. Miner. Res. 2002, 17:406-414.
5. Minamide A., Boden S.D., Viggeswarapu M., Hair G.A., Oliver C., Titus L. Mechanism of bone formation with gene transfer of the cDNA encoding for the intracellular protein LMP-1. J. Bone. Joint. Surg. Am. 2003, 85-A:1030-1039.
6. Sangadala S., Boden S.D., Viggeswarapu M., Liu Y., Titus L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf1 resulting in decreased ubiquitination of Smads. J. Biol. Chem. 2006, 281:17212-17219.
7. Chan E.D., Riches D.W. Potential role of the JNK/SAPK signal transduction pathway in the induction of iNOS by TNF-alpha. Biochem. Biophys. Res. Commun. 1998, 253:790-796.
8. Kleinert H., Pautz A., Linker K., Schwarz P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 2004, 500:255-266.
9. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
10. Mercurio F., Manning A.M. NF-kappaB as a primary regulator of the stress response. Oncogene 1999, 18:6163-6171.
11. Chang J., Wang Z., Tang E., Fan Z., McCauley L., Franceschi R., et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 2009, 15:682-689.
12. Baeuerle P.A., Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988, 242:540-546.
13. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
14. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
15. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 1999, 71:479-500.
16. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
17. Tsutsumi R., Ito H., Hiramitsu T., Nishitani K., Akiyoshi M., Kitaori T., et al. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol. Int. 2008, 28:727-736.
18. Lu S.C., Wu H.W., Lin Y.J., Chang S.F. The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. Am. J. Physiol. Cell. Physiol. 2009, 296:C1133-1139.
19. Rajapakse N., Kim M.M., Mendis E., Kim S.K. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. Immunology 2008, 123:348-357.
20. Ci X., Song Y., Zeng F., Zhang X., Li H., Wang X., et al. Ceftiofur impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-kappaB and MAPK. Biochem. Biophys. Res. Commun. 2008, 372:73-77.
21. Itoh K., Udagawa N., Kobayashi K., Suda K., Li X., Takami M., et al. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 2003, 170:3688-3695.
22. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 2002, 13:52-56.
23. Becker-Hapak M., McAllister S.S., Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods 2001, 24:247-256.
24. Sangadala S., Okada M., Liu Y., Viggeswarapu M., Titus L., Boden S.D. Engineering, cloning, and functional characterization of recombinant LIM mineralization protein-1 containing an N-terminal HIV-derived membrane transduction domain. Protein. Expr. Purif. 2009, 65:165-173.
25. Park E., Quinn M.R., Wright C.E., Schuller-Levis G. Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells. J. Leukoc. Biol. 1993, 54:119-124.
26. Liu Y., Titus L., Barghouthi M., Viggeswarapu M., Hair G., Boden S.D. Glucocorticoid regulation of human BMP-6 transcription. Bone 2004, 35:673-681.
27. Arenzana-Seisdedos F., Virelizier J.L. Interferons as macrophage-activating factors. II. Enhanced secretion of interleukin 1 by lipopolysaccharide-stimulated human monocytes. Eur. J. Immunol. 1983, 13:437-440.
28. Chokri M., Freudenberg M., Galanos C., Poindron P., Bartholeyns J. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer. Res. 1989, 9:1185-1190.
29. Haynes D.R. Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis. Res. Ther. 2007, 9:104.
30. Hardy R., Cooper M.S. Bone loss in inflammatory disorders. J. Endocrinol. 2009, 201:309-320.
31. Udagawa N., Kotake S., Kamatani N., Takahashi N., Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis. Res. 2002, 4:281-289.
32. Ali T., Lam D., Bronze M.S., Humphrey M.B. Osteoporosis in inflammatory bowel disease. Am. J. Med. 2009, 122:599-604.
33. Ralston S.H., Ho L.P., Helfrich M.H., Grabowski P.S., Johnston P.W., Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J. Bone. Miner. Res. 1995, 10:1040-1049.
34. van't Hof R.J., Armour K.J., Smith L.M., Armour K.E., Wei X.Q., Liew F.Y., et al. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7993-7998.
35. Kundu J.K., Surh Y.J. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat. Res. 2005, 591:123-146.
36. Schindeler A., Little D.G. Ras-MAPK signaling in osteogenic differentiation: friend or foe?. J. Bone Miner. Res. 2006, 21:1331-1338.
37. Rao K.M., Meighan T., Bowman L. Role of mitogen-activated protein kinase activation in the production of inflammatory mediators: differences between primary rat alveolar macrophages and macrophage cell lines. J. Toxicol. Environ. Health. A. 2002, 65:757-768.